

Award Number: DAMD17-03-1-0315

TITLE: Estrogen Metabolism and Prostate Cancer Risk: A Prospective Study

PRINCIPAL INVESTIGATOR: Paola Muti, M.D.

CONTRACTING ORGANIZATION: Italian National Cancer Institute
Rome 00144, Italy

REPORT DATE: May 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-05-2006			2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 MAY 2005 - 30 APR 2006	
4. TITLE AND SUBTITLE Estrogen Metabolism and Prostate Cancer Risk: A Prospective Study					5a. CONTRACT NUMBER	
					5b. GRANT NUMBER DAMD17-03-1-0315	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Paola Muti, M.D. E-Mail: muti@ifo.it					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Italian National Cancer Institute Rome 00144, Italy					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT: Prostate cancer is the most common cancer among men in the United States (IARC, 1995) and the second most common in the European Community (IARC, 1995). The causes of prostate cancer, however, remain largely unknown, with age, race, and family history being the only established risk factors (Nomura et al., 1997). The prostate gland has historically been considered the prototype of an androgen-dependent organ. However, there is evidence that estrogens may induce mitosis of prostatic epithelial cells in many species, including humans (Leav et al., 1978; Schulze et al., 1987). This report analyzes the association between prostate cancer and estrogen metabolism investigated in a case-control study. In particular, we tested the hypothesis that the pathway favoring 2-hydroxylation over 16 α -hydroxylation may be associated with a decrease in prostate cancer risk. This is the annual report for the third year of the study. During the third year of activity, we completed the definition of the large dataset of the study, conducted quality control procedures on the collected data and develop new laboratory procedures for the determination of the estrogen metabolites using gas-chromatography. The determinations are in now in advanced phase of progress.						
15. SUBJECT TERMS Prostate Cancer, Estrogens, Epidemiological Study						
16. SECURITY CLASSIFICATION OF:				17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	19b. TELEPHONE NUMBER (include area code)			

TABLE OF CONTENTS

	Page
Cover	
SF 298	2
Table of Contents	3
Introduction	4
Body	5
Conclusions	8
References	8
Appendix	10

INTRODUCTION

Prostate cancer is the most common cancer among men in the United States (IARC, 1995) and the second most common in the European Community (IARC, 1995). The causes of prostate cancer, however, remain largely unknown, with age, race, and family history being the only established risk factors (Nomura et al., 1997). The prostate gland has historically been considered the prototype of an androgen-dependent organ. However, there is evidence that estrogens may induce mitosis of prostatic epithelial cells in many species, including humans (Leav et al., 1978; Schulze et al., 1987).

This report analyzes the association between prostate cancer and estrogen metabolism investigated in a case-control study. In particular, we tested the hypothesis that the pathway favoring 2-hydroxylation over 16 α -hydroxylation may be associated with a decrease in prostate cancer risk.

This is the annual report for the third year of the study. During the third year of activity, we completed the definition of the large dataset of the study, conducted quality control procedures on the collected data and develop new laboratory procedures for the determination of the estrogen metabolites using gas-chromatography. The determinations are in now in advanced phase of progress.

BODY OF REPORT

In accordance with the Statement of Work, during the third budget year, we are conducting hormone determinations as part of the planned activity are preparing the database for data analysis.

Background

Follow-up of the cohort: We completed the re-call and follow-up of the Western-New York cohort (WNYHC) for the identification of the incident prostate cancer cases and their related control subjects. The follow-up was conducted in collaboration with another NIH-funded study, the “Epidemiology of Type-2 Diabetes” study, which is a prospective cohort study based on the same WNYHC cohort (RO1 DK 60587, Dr. R. Donahue, PI, Dr. P. Muti, Co-PI).

The re-call of the cohort started in January 2003. The re-call included participants without history of cancer, cardiovascular diseases, and clinically defined type-2 diabetes at baseline interviewed between 1996-2001. The re-call was also limited to those cohort participants with stored biological samples. Thus, we started the re-call and the follow-up process with a sample of **1,150 cohort participants**.

Of the 1,150 cases :-

- **52** were not eligible for medical reasons (too ill with diseases other than those mentioned before),
- **46** had died (for causes other than prostate cancer),
- **22** had moved out of the Erie and Niagara Counties,
- **117** were not contactable by mail or phone.

Overall, we had a sample of **913** re-called participants. Among the **913** participants, we identified :-

- **41** incident prostate cancer cases,
- **232** cases refused to participate in the study (they refer, in the short telephone interview, to having not been diagnosed with prostate cancer),
- **40** were scheduled but then cancelled the appointment,
- **8** were still in-process at the end of the follow-up period (September 30, 2004).

Thus, there were **592** participants available as control subjects.

During the study period, we monitored the occurrence of prostate cancer among the successfully contacted participants. All procedures to re-call, interview and collect biological specimens from the WNYHC Study were similar to the procedures used for baseline recruitment. All eligible participants were initially re-contacted by letter and then by phone (up to twelve callbacks). Participants were invited to attend our recruitment center at the Department of Social and Preventive Medicine, Buffalo, New

York for the clinical examination and to answer questions related to the occurrence of prostate cancer diagnosis between the baseline examination and the re-call time.

Definition of the matched case-control pairs.

Case Identification: Incident Prostate Cancer Cases: Prostate cancer cases recruited in the study were men who have been diagnosed with incident cytologically and/or histologically confirmed prostate cancer after their recruitment (date at first interview) in the WNYHC Study and before the end of the cohort follow-up period (September, 30, 2004). Prostate cancer cases were identified by their own report at the re-call of the cohort. 32 cases have been validated by their clinical records, while the remaining 9 cases are in the process to be validated. At recruitment, each cohort member signed a consent form giving us permission to request copies of their clinical charts in cases of pathological events related to the WNYHC Study investigations. Through these clinical charts, we are validating the information collected from participants.

Control Identification: Eligible controls were all male members of the WNYHC Study who, based on their report, were not diagnosed with prostate cancer at the diagnosis of the related case. For each prostate cancer case, four controls will be randomly chosen after matching for:

- a) age (within 3 years);
- b) race;
- c) recruitment date

to control for the effect of long-term preservation of stored urine.

To increase the power of the study (and to reduce the effects of non-diagnosed prostate cancer cases among controls), we used a 1:4 ratio for cases and controls. Therefore, the study hormone determinations will be conducted on 41 prostate cancer cases and 164 control subjects.

At present, we have conducted a series of quality control procedures for laboratory determination of the estrogen metabolites included in the study. From these procedures, we have identified gas-chromatography as the most reliable method to assay these biomarkers. The actual determinations are on-going.

KEY RESEARCH ACCOMPLISHMENTS

- Completed the follow-up of the cohort
- Completed quality control procedures to ensure the completeness (reliability?) of the follow-up
- Completed quality control setting for hormone bio-assays
- Completed new analysis of secondary sexual characteristics and prostate cancer risk, based on a previously DOD-funded prostate cancer study

REPORTABLE OUTCOMES

Publications and Presentations

At this time, there are no results or publications coming directly from this grant because we still completing the study. However, Dr. Muti has published, or has in press, research on hormone-related cancer using a previously collected data set on hormone and prostate cancer (the dataset was originated from a previously DOD-funded study). She has submitted a paper for publication on the relationship between Indicators of Sexual and Somatic Development and Adolescent Body Size in Relation to Prostate Cancer Risk: Results from a case-control study.

In 2005-2006, Dr. Muti has published other papers on hormones and cancer, listed below:

- 1) Barba M, McCann S, **Muti P**, Stranges S, Fuhrmann B, Trevisan M, Freudenheim JL *Perinatal Exposures and Breast Cancer Risk: a Case Control Study (in press, Cancer Causes and Control)*
- 2) Colombo C, **Muti P**, Pala V, Cavalleri A, Venturelli E, Locardi M, Berrino F, Secreto G. *Plant-based diet, serum fatty acid profile, and free radicals in postmenopausal women: the diet and androgens (DIANA) randomized trial. Int J Biol Markers. 2005 Jul-Sep;20(3):169-76*
- 3) McCann se, Kulkarni S, Trevisan M, Vito D, Nie J, Edge S, **Muti P**, Freudenheim JL *Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status (in press, Breast Cancer Research and Treatment)*
- 4) *Cavaliere E, Chakravarti D, Guttenplan J, Muti P, Jankowiak R, Rogan E, Russo J, Santen R, Sutter T* Catechol Estrogen Quinones as Initiators of Breast and Other Human Cancers. Implications for Cancer Prevention and Biomarkers of Susceptibility (submitted for publication)

She has also presented new study results from other studies conducted, at the Meetings of the American Association for Cancer Research:

- 1) **Teter B***, Cavalleri A, Fuhrman B, Krogh V, Barba M, Schünemann HJ, Evangelista A, Del Sette D, Micheli A, Meneghini E, Secreto G, Berrino F, **Muti P** *Urinary Nocturnal Excretion of 6-sulfatoxymelatonin and Breast Cancer Risk* Meeting of the American Association for Cancer Research "Frontiers in Cancer Prevention Research", Baltimore, October 2005

- 2) **Barba M***, Cavalleri A, Schünemann HJ, Krogh V, Evangelista A, Secreto G, Micheli A, Qi Zhou, Fuhrman B, Reter B, Berrino F, Muti P *Effects of different storage temperatures on 6-Sulfatoxymelatonin concentration in urin* Meeting of the American Association for Cancer Research “Frontiers in Cancer Prevention Research”, Baltimore, October 2005
- 3) Crespo CJ, **Fuhrman B***, Smit E, Freudenheim JL, Garcia Palmieri M, Lee IM, Muti P, Marrero FR. *Anthropometric Measures and Fasting Glucose as Predictors of Fatal Prostate Cancer among Puerto Rican Men: The Puerto Rico Heart Health Study Cohort* Meeting of the American Association for Cancer Research “Frontiers in Cancer Prevention Research”, Baltimore, October 2005
- 4) Barba Maddalena, **Terrenato Irene**, Fuhrman Barbara, Teter Barbara, Schunemann Holger, Muti P. *Secondary sexual characteristics and body size at different ages in relation to risk of prostate cancer: results from a case-control study* Annual Meeting American Association for Cancer Research, Washington, April 2006

Two of these studies have been submitted for publication.

In addition, Dr. Muti has several other manuscript submitted for publication on hormone and related factors and cancer.

CONCLUSIONS

The phase of hormone determinations for this grant is on-going. Therefore, there are no conclusions to report at this time.

REFERENCES

- 1) Barba M, McCann S, **Muti P**, Stranges S, Fuhrmann B, Trevisan M, Freudenheim JL *Perinatal Exposures and Breast Cancer Risk: a Case Control Study (in press, Cancer Causes and Control)*
- 2) Colombo C, **Muti P**, Pala V, Cavalleri A, Venturelli E, Locardi M, Berrino F, Secreto G. *Plant-based diet, serum fatty acid profile, and free radicals in postmenopausal women: the diet and androgens (DIANA) randomized trial.* Int J Biol Markers. 2005 Jul-Sep;20(3):169-76

- 3) McCann se, Kulkarni S, Trevisan M, Vito D, Nie J, Edge S, **Muti P**, Freudenheim JL *Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status (in press, Breast Cancer Research and Treatment)*

APPENDIX

- 1) **Appendix 1:** Barba M, Terrenato I, Schünemann HJ, Fuhrman B, Teter B, Gallucci M, D'Amato A, **Muti P**. *Secondary sexual characteristics and adolescent body size in relation to risk of prostate cancer: results from a case control study (submitted for publication)*

Secondary sexual characteristics and adolescent body size in relation to risk of prostate cancer: results from a case-control study.

Barba Maddalena¹, Terrenato Irene¹, Schünemann Holger J. ^{1,2,3}, Fuhrman Barbara⁴, Teter Barbara⁴, Gallucci Michele⁵, Muti Paola^{1,6}

¹Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

²Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

³Department of Medicine, University at Buffalo, State University of New York, Buffalo, New York, USA

⁴Department of Social and Preventive Medicine, State University at Buffalo, Buffalo, New York, USA

⁵Department of Urology, Italian National Cancer Institute Regina Elena, Rome, Italy

⁶Department of Epidemiology, School of Public Health, Harvard University, Massachusetts, USA

Abstract

BACKGROUND: Prostate cancer is currently the most frequently diagnosed cancer and the second leading cause of cancer death among men in the United States. Although it is a disease of older age, early physical growth and development might be important determinants of prostate cancer risk during adult life. Early onset of secondary sexual characteristics and adolescent anthropometrical characteristics have been investigated in relation to prostate cancer risk with inconsistent results.

OBJECTIVE: The purpose of this study was to examine the relationship between age at first shaving of facial hair, age at maximum shoe size and body size at age 10-13, considered as indicators of sexual and somatic development and surrogates of exposure to sex steroid hormones, and risk of prostate cancer.

METHODS: We conducted a population-based case-control study in Erie and Niagara counties, New York, USA. Cases included 64 men, aged 49-83 years, diagnosed with incident, primary, histologically confirmed and clinically apparent (stage B and higher) prostate cancer. Controls included 218 men, frequency matched on age and residential area. Information regarding the variables of interest were self-reported. We compared adjusted means of age at first shaving and age at maximum shoe size and calculated the odds of body size at age 10-13 using logistic regression models.

RESULTS: Cases and controls did not statistically differ with regard to age at first shave (18.0 vs. 17.8, $p = 0.46$), but they differed significantly for age at maximum shoe size (20.1 vs. 17.6, $p < 0.05$). In referral to body size at age 10-13, participants who defined themselves as heavy and heavier than peers had a decreased prostate cancer risk

when compared to participants who defined themselves thinner than peers (OR: 0.36 95% CI: 0.15-0.83 and OR: 0.38 95% CI 0.17-0.87, respectively).

CONCLUSIONS: Based on our study results, prostate cancer risk was statistically related to age at maximum shoe size and body size at age 10-13, but not to age at first shaving. Our findings underline the relevance of exposure to sex steroid hormones during critical windows of prostate gland development, evaluated throughout surrogates of hormonal milieu, in affecting prostate cancer risk later in adulthood.

Introduction

Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer death among men in Western countries (1). Notwithstanding the importance of this malignancy, little is understood about its cause. Age, family history, race and country of residence are the only well established risk factors (2).

Over the last decades, the body of evidence regarding a major role of sex steroid hormones, particularly androgens, in prostate carcinogenesis has been considerably growing. A powerful tumor-promoting activity of androgens clearly emerges from animal data (3), while epidemiologic studies have produced conflicting results (4-8). Difficulties in identifying etiologically relevant time periods of exposure to sex steroid hormones through investigations conducted during adult life might partly explain inconsistency across epidemiologic studies.

It has been suggested that prostate sensitivity to hormonal influences widely varies over lifetime with particularly important influence during puberty, when this gland achieves its full development (9-10). At the same time, sex steroid hormones play a key role in

regulating sexual and somatic maturation in both genders, concurring to determine secondary sexual characteristics and measures of body size at different ages (11-12).

In this population-based case-control study we investigated the relationship between surrogates of hormonal milieu in adolescence and prostate cancer risk later in adulthood, focusing on self reported age at first shaving, age at maximum shoe size and body size at age 10-13.

Materials and Methods

Study Subjects

We conducted a case-control study of incident, primary, histologically confirmed prostate cancer cases in Erie and Niagara counties, NY (the PROMEN study). We previously described the recruitment of study participants (13). In brief, from December 1998 to April 2001, 504 prostate cancer cases were identified. Of these 504, 163 met eligibility criteria, and were approved by the urologists and invited to join the PROMEN study. After being contacted, 50 men refused to participate. Thus, among the eligible participants, 70% (113/163) participated in the study. Twenty-five prostate cancer cases did not provide blood samples and 24 had missing data items, thus the present analyses are conducted on 64 cases.

To exclude latent prostate carcinomas that one cannot distinguish from those that would not progress to clinical disease (real latent carcinoma) and those detected in a very early phase of their progression, the present study included only patients with clinically apparent disease [stage B and greater by the staging system proposed by Catalona (14)].

To standardize the stage of the disease across hospitals, a screening form developed in the context of the PROMEN study was completed by a trained nurse case-finder using the hospital pathology records. The forms and hospital records were reviewed by the principal investigator (P. Muti) of the study.

In recruiting controls, since latent prostate carcinoma has a high prevalence in men over 50 (15), we evaluated serum prostate specific antigen (PSA). Those found to have a PSA level higher than 4 ng/ml were excluded from the control group, in accordance with the criterion adopted by the American College of Preventive Medicine (16), until the completion of further diagnostic procedures, that allowed us to clarify which of the two groups they truly belonged on the basis of their correct case-control status. We identified eight prostate cancer cases because of PSA determination in subjects who initially were recruited as controls.

Three hundred and seventeen of the 513 subjects contacted during the study period were willing to participate (61,8%). Participants with missing data for any of the variables of interest were excluded, thus the final sample includes 218 controls.

Information regarding age at first shave, age at maximum shoe size and body size at age 10-13 were self reported. With regard to body size at age 10-13, participants defined themselves thinner than, as heavy as or heavier than peers during the considered period.

Trained interviewers collected extensive data on demographics and other study variables during in person interviews. Waist circumference was measured by trained personnel using a standardized protocol. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters (kg/m^2).

All participants provided informed consent; the Human Subjects Review Board of the University at Buffalo, School of Medicine and Biomedical Science and each of the participating hospitals approved procedures for protection of human subjects in the study.

Statistical Analysis

Distributions for all variables of interest were examined. In order to evaluate the statistical significance of any associations between case/control status and participant characteristics, we used t-tests for continuous variables and Pearson's chi-square tests for categorical variables.

Adjusted means and standard errors for age at first shave and age at maximum shoe size (continuous variables) were obtained using a general linear model, while unconditional logistic regression was used to compute crude and adjusted odds ratios (OR) and 95% confidence interval (CI) for body size at age 10-13 (categorical variable). The same models were used to test variables for possible interactions (we considered significant an interaction with a p-value < 0.05) . In assessing risk estimates, age in years, race and BMI were considered as possible confounders. Each of the three outcome variables (age at first shaving, age at maximum shoe size and body size at age 10-13) was further mutually adjusted for the others. Subgroup analyses were also performed stratifying by race.

Given the different response rate between cases and controls, we compared the two groups on the basis of indicators of social-economic status and lifestyle factors available from our in-person interview (years of education, annual income, marital status, smoking status).

Furthermore, we examined the characteristics of men included in the present analyses (cases = 64 and controls = 218) and those of men who had been excluded because of missing data (cases = 24 and controls = 33) by case-case and control-control comparison.

Data were analyzed using SPSS version 11.5 (SPSS, Inc., Chicago, IL).

Results

Table 1 shows descriptive characteristics of study participants. When compared to controls, prostate cancer cases were more likely to be slightly younger, to have higher values of waist circumference and BMI and to be Afro-Americans. Non-significant associations were observed for history of enlarged prostate, familiar history of prostate cancer, and years of education.

In table 2, we report unadjusted and adjusted means for age at first shave and age at maximum shoe size, as well as crude and adjusted ORs and 95% CI for body size at age 10-13. When comparing mean values for age at first shaving and age at maximum shoe size, cases were likely to be older than controls (17.7 vs. 17.1, $p < 0.05$ and 19.7 vs. 17.9, $p < 0.05$, respectively). After adjustment for age, race and BMI, cases and controls did no longer statistically differ with regard to age at first shave (18.0 vs. 17.8, $p = 0.46$), while estimates resulted significantly different in terms of age at maximum shoe size (20.1 vs. 17.6, $p < 0.05$). With reference to body size at age 10-13, participants who defined themselves as heavy as peers and heavier than peers showed a decreased prostate cancer risk when compared to participants who defined themselves thinner than peers (OR: 0.36 95% CI: 0.15- 0.83 and OR: 0.38 95% CI 0.17- 0.87,

respectively). In computing risk estimates for each of the considered variables, neither mutual adjustment for the remaining two variables nor stratifying by race did significantly affect prostate cancer risk. Furthermore, no evidence for interaction was found in these data for any of the variables of interest.

When comparing cases and controls on the basis of indicators of social economic status and lifestyle factors, no significant differences emerged. Finally, from the comparative analysis by case-case and control-control comparison, participants who had been included in the present analyses differed from those who had been excluded because of missing data items exclusively for waist circumference ($p < 0.05$ in both groups).

Discussion

On the basis of our case-control study results, prostate cancer risk was statistically related to age at maximum shoe size and body size at age 10-13, but not to age at first shaving. Our findings underline the relevance of exposure to sex steroid hormones during critical windows of prostate gland development in affecting prostate cancer risk later in adulthood.

Our study has several strengths. We had a population-based sample with clearer distinction between cases and controls than in previously conducted studies. This is the result of an innovative recruiting strategy, that is, limiting eligibility for enrolment as cases to men who have been diagnosed with advanced cancer stages (stage B and higher). This approach has been helpful in reducing misclassification by eliminating early stage prostate cancers, as they are not distinguishable from latent diseases that might be prevalent among controls. With the same aim, subjects were eligible for

recruitment as controls on the basis of a PSA determination, which helped to ensure that the control group was free from latent prostate cancer.

Additionally, in-person interviews conducted by trained personnel allowed the collection of a great variety of data on demographics, lifestyle, personal risk factors for prostate cancer (e.g. familial history) and three different surrogates of hormonal milieu relative to adolescence.

This study also has several limitations. A possible selection bias might have derived from a lower response rate among controls than among cases (61.8% vs. 69%). To address this issue, we compared cases and controls on the basis of several indicators of social-economic status and lifestyle factors available from our in-person interview. We found no evidence that controls were more health conscious or healthier than cases.

Another source of bias might have been introduced in our study by excluding study participants with missing data items for the variables of interest. Comparative analyses by case-case and control-control comparison showed significant differences exclusively for waist circumference, which did not represent outcome variables in the present study. The reliance on self-reported age at first shave, age at maximum shoe size and body size at age 10-13 represents another possible study limitation. Independently on the study design, with adolescence being the exposure period under investigation, self-reporting represents the assessment methodology consistently used to collect information regarding the variables of interest across several studies conducted over the past two decades (17-20). Besides, scientific evidence shows a high degree of reproducibility of self-reported past body size measures in older persons (21).

Our study small sample size might have limited our ability in detecting significant differences for all the variables of interest. Nevertheless our findings add evidence to the potential role of preadult hormonal exposures in affecting prostate cancer risk later in adulthood, thus contributing to reduce a major gap currently existing in scientific knowledge of prostate carcinogenesis.

Although potentially of great meaning in clarifying aspects of prostate carcinogenesis, the relevant exposure period for the association between preadult hormonal influences and prostate cancer has been addressed in a few studies, extremely heterogeneous (17-20).

To our knowledge, the potential relationship between age at shaving initiation and prostate cancer risk has been exclusively investigated in a large, multiracial cohort study conducted by Habel and colleagues. Consistent with our study results, there was no overall association between age at shaving initiation and prostate cancer risk, although data lent some support for a weak, non-significant association among non-white men who started shaving at a younger age (17).

The search of scientific literature with regard to previously conducted studies investigating the association of age at maximum shoe size with prostate cancer risk did not produce any result, making at the same time our study innovative and our finding not comparable.

Results from two recently conducted case-control studies did not provide any support to the association between past body size measures and prostate cancer risk (18-19). Differences in the study design (18), variables of interest and considered period of exposures (19), might partly explain the discrepancy with our results.

Consistent with our study, higher reported level of adiposity at age 10, evaluated by mean of pictograms representing figures ranging from thin to obese, resulted prospectively associated with a lower risk of prostate cancer from the analyses conducted by Giovannucci and colleagues using data from the Health Professionals Follow-up study (20).

Adolescence represents a critical window in prostate development, being this gland essentially dormant until its occurrence. Over this lifetime period, sex steroid hormones play a central role in the acquisition and maturation of an individual sexual and somatic characteristics, as well as in the achievement of prostate gland full development.

Furthermore, since sex steroid hormones are well documented regulators of prostate epithelial cell mitogenicity (22), the hormonal milieu associated with growth and development might influence the likelihood of the occurrence and propagation of mutations at a cellular level.

At this regard, scientific literature is consistent in providing evidence of prostate cancer precursor lesions among men in their twenties, suggesting an early beginning of the carcinogenetic process and an important role of early life exposures (23).

Overweight and obesity in young males are associated with well documented endocrine aberrations, including higher estrogen and lower testosterone levels (24-25). This might provide some protection against prostate cancer, explaining, with regard to our study results, a lower risk among cases who reported a greater body size at age 10-13. Conversely, thinner young men are exposed to the same hormonal influences in an opposite balance.

In our study, cases showed a consistent delay in completing their sexual and somatic development, as expressed by an older age at shaving (although non significant in our limited sample) and at reaching maximum shoe size. This might suggest a lower sensitivity to testosterone, as a consequence of the exposure to higher circulating levels than in heavier participants. Further speculation about the underlying biological mechanisms would be only theoretical, being the scientific evidence very limited.

Conclusively, our need to reach a better knowledge about the preadult and, more specifically, the adolescent exposure to sex steroid hormones is undeniable and in deep contrast with the current lack of scientific evidence. Further work is needed in terms of specifically targeted studies, which are expected to be more homogeneous with regard to the study design, variables of interest and period of exposure, being these issues of crucial importance in the comparison and interpretation of the scientific results.

References

1. Giovannucci E. Epidemiologic characteristics of prostate cancer. *Cancer* 1995, 75:1766-1777
2. Bosland MC. The role of steroid hormones in prostate carcinogenesis. *J Natl Cancer Inst Monogr* 2000, 39-66
3. Bosland MC, Dreef-Van Der Meulen, HC, Sukumar S, Ofner P, Leav I, Han X, Liehr JG. Multistage prostate carcinogenesis: the role of hormones. In: Harris CC, Hirohashi S, Ito N, Pitot HC, Sugimura T, Terada M, Yokota J, editors.

Multistage carcinogenesis. Japan Sci Soc Press, Tokyo/CRC Press. Boca Raton (FL):CRC Press 1992;109-23

4. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. *Lancet* 1992;339:887-9
5. Lookingbill PD, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. *J Clin Endocrinol Metab* 1991;72:1242-8
6. de Jong FH, Oishi K, Hayes RB, Bogdanowicz JF, Raatgever JW, van der Maas PJ, et al. Peripheral hormone levels in controls and patients with prostate cancer or benign prostatic hyperplasia: results from the Dutch- Japanese case-control study. *Cancer Res* 1991;51:3445-50
7. Ellis L, Nyborg H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. *Steroids* 1992;57:72-5
8. Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. *Cancer Epidemiol Biomarkers Prev* 1995;4:735-41
9. Diamandis EP, Yu H. Does prostate cancer start at puberty? *Clin Lab Anal.* 1996;10(6):468-9
10. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. *J Natl Cancer Inst.* 1997 Mar 5;89(5):385-9

11. Farthing MJ, Mattei AM, Edwards CR, Dawson AM. Relationship between plasma testosterone concentrations and male facial hair growth. *Br j Dermatol* 1982 107:559-564
12. Juul A. The effects of oestrogens on linear bone growth. *Hum Reprod Update* 2001 May-June;7 (3):303-13
13. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry J 3rd, Schunemann H, Freudenheim JL, Hill H, Carruba G, Bradlow L. Urinary estrogen metabolites and prostate cancer: A case-control study in the United States. *Cancer Causes Control* 2002;13:947-955
14. Catalona WJ. Diagnosis, staging, and surgical treatment of prostatic carcinoma. *Arch Inter Med* 1987;147:361-380
15. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gelleei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius h. Latent carcinoma of prostate at autopsy in seven areas. *The International Agency for research on Cancer* 1977,20:680-688
16. Moul JW. Screening for prostate cancer in American men. *Curr Urol Rep.* 2000;1(1):57-64
17. Habel LA, Van Dean Eeden SK, Friedman GD. Body size, Age at shaving Initiation, and Prostate Cancer in a Large, Multiracial Cohort. *The Prostate* 2000; 43:136-143
18. Dal Maso L, Zucchetto A, La Vecchia C, Montella M, Conti E, Canzonieri V, Salamini R, Negri E, Garbuglio A, Franceschi S. Prostate cancer and body size

- at different ages: an Italian Multicentre case-control study. *B J Cancer* 2004;90: 2176-2180
19. Giles GG, Severi G, English DR, McCredie MRE, MacInnis R, Boyle P, Hopper JL. Early growth, adult body size and prostate cancer risk. *Inter J Cancer* 2002;103: 241-245
 20. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, Body Weight, and Risk of Prostate Cancer. *Cancer Epidemiol Biomarkers Prev* 1997;6: 557-563
 21. Klipstein-Grobusch K, Kroke K, Boeing H Reproducibility of self-reported past body weight. *Eur J Cancer Nutrit* 1998;52:525-528
 22. Sciarra F. Sex steroids and epidermal growth factor in benign prostatic hyperplasia 1995; 761:66-78
 23. Sakr WA, Haas GP, Cassin BF, Pontes FE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. *J. Urol* 1993;150:379-385
 24. Pasqualini R, Casimirri F, Cantobelli S, Melchionda N, Labate AM, Fabbri R, Capelli M, Bortoluzzi L. Effects of obesity and body fat distribution on sex hormones and insulin in men. *Metabolism* 1991;40:101-104
 25. Field AE, Colditz GA, Willett WC, Lonoscope C, McKinlay JB. the relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex-binding globulin in middle aged men. *J Clin Endocrinol Metab* 1994;79:1310-1316

Table 1. Participants Descriptive Characteristics¹ by Case-Control Status (n=282).

PROMEN STUDY 1998-2001

	Cases (n = 64)	Controls (n = 218)
Age (yr)	67.6 (7.9)	70.1 (6.2)*
Waist circumference (cm)	105.6 (13.6)	101.8 (12.2)*
BMI²	30.2 (5.1)	28.5 (4.6)*
Education (yr)	13.1 (2.9)	13.0 (2.7)
History of enlarged prostate		
% Yes	56.2	44.0
Familial history of Pca		
% Yes	15.6	10.1
African-American		
% Yes	32.8	7.3***

specified ¹ Values are means and standard deviations (SD), unless otherwise

² BMI calculated by Quetelet's index: weight(kg)/height (m²)
 * p < 0.05 ** p < 0.01 *** p < 0.001

Table 2. Prostate Cancer Risk Estimates. PROMEN STUDY, 1998-2001.

		Unadjusted means and Standard Deviation	Adjusted¹ Means and Standard Error		
Age at first shave	Cs	17.7 (2.4)	18.0 (0.2)		
	Co	17.1* (1.8)	17.8 (0.3)		
Age at maximum shoe size	Cs	19.7 (9.4)	20.1 (0.7)		
	Co	17.9* (3.5)	17.6* (0.7)		
Body size at age 10-13	cs/co	Crude OR	95% CI	Adjusted OR	95% CI
Thinner than peers	18/27	1		1	
As heavy as peers	22/104	0.32**	0.15-0.67	0.36*	0.15- 0.83
Heavier than peers	24/87	0.41*	0.20-0.87	0.38*	0.17- 0.87

¹ Adjusted for age, race and BMI

* p< 0.05 ** p<0.01